Refractory multiple myeloma – pipeline review, h2 2012

312 views
261 views

Published on

2012 || Oncology || Refractory Multiple Myeloma – Pipeline Review, H2 2012 || Aarkstore.com

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
312
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
6
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Refractory multiple myeloma – pipeline review, h2 2012

  1. 1. Aarkstore.com announces, The Latest market research report is available inits vast collection:Refractory Multiple Myeloma – Pipeline Review, H2 2012http://www.aarkstore.com/reports/Refractory-Multiple-Myeloma-Pipeline-Review-H2-2012-220603.htmlRSS link of Global Markets Directhttp://www.aarkstore.com/feeds/Global-Markets-Direct.xmlSummaryGlobal Markets Direct’s, Refractory Multiple Myeloma - Pipeline Review, H2 2012,provides an overview of the Refractory Multiple Myeloma therapeutic pipeline. Thisreport provides information on the therapeutic development for Refractory MultipleMyeloma, complete with latest updates, and special features on late-stage anddiscontinued projects. It also reviews key players involved in the therapeuticdevelopment for Refractory Multiple Myeloma. Refractory Multiple Myeloma -Pipeline Review, H2 2012 is built using data and information sourced from GlobalMarkets Direct’s proprietary databases, Company/University websites, SEC filings,investor presentations and featured press releases from company/university sitesand industry-specific third party sources, put together by Global Markets Direct’steam.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Refractory Multiple Myeloma.- A review of the Refractory Multiple Myeloma products under development by
  2. 2. companies and universities/research institutes based on information derived fromcompany and industry-specific sources.- Coverage of products based on various stages of development ranging fromdiscovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combinedtherapeutics.- Coverage of the Refractory Multiple Myeloma pipeline on the basis of route ofadministration and molecule type.Table of contents:List of Tables 8List of Figures 9Introduction 10Global Markets Direct Report Coverage 10Refractory Multiple Myeloma Overview 11Therapeutics Development 12An Overview of Pipeline Products for Refractory Multiple Myeloma 12Refractory Multiple Myeloma Therapeutics under Development by Companies 14Refractory Multiple Myeloma Therapeutics under Investigation byUniversities/Institutes 16Late Stage Products 18Comparative Analysis 18Mid Clinical Stage Products 19Comparative Analysis 19Early Clinical Stage Products 20Comparative Analysis 20Refractory Multiple Myeloma Therapeutics – Products under Development byCompanies 21Refractory Multiple Myeloma Therapeutics – Products under Investigation byUniversities/Institutes 22Companies Involved in Refractory Multiple Myeloma Therapeutics Development 23Bristol-Myers Squibb Company 23Abbott Laboratories 24Eli Lilly and Company 25Merck & Co., Inc. 26Piramal Healthcare Limited 27
  3. 3. Millennium Pharmaceuticals, Inc. 28Cephalon, Inc. 29ImmunoGen, Inc. 30Pfizer Inc. 31Celgene Corporation 32Onyx Pharmaceuticals, Inc. 33List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Pipeline Review, H2 2012http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H22012&PubId=&pagenum=1Cholangiocellular Hepatoma – Pipeline Review, H2 2012Hormone Refractory Breast Cancer – Pipeline Review, H2 2012Muscle Invasive Bladder Cancer (MIBC) – Pipeline Review, H2 2012Refractory Multiple Myeloma – Pipeline Review, H2 2012Epithelial Ovarian Cancer – Pipeline Review, H2 2012Neuro Endocrine (Carcinoid) Carcinoma – Pipeline Review, H2 2012
  4. 4. B-Cell Leukemia – Pipeline Review, H2 2012Malignant Neoplasms – Pipeline Review, H2 2012Recurrent Malignant Glioma – Pipeline Review, H2 2012Endobronchial Cancer – Pipeline Review, H2 2012Leiomyosarcoma – Pipeline Review, H2 2012Transitional Cell Cancer (Urothelial Cell Cancer) – Pipeline Review, H2 2012Esophageal Tumor – Pipeline Review, H2 2012Malignant Pleural Mesothelioma – Pipeline Review, H2 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcarehttp://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals andHealthcare&PubId=&pagenum=1You can also request for sample page of above mention reports onsample@aarkstore.comFor More details Plz do contact :Aarkstore EnterpriseLavanya
  5. 5. Phone:08149852585Email: enquiry@aarkstore.com

×